Takeda Pharmaceutical
About Takeda Pharmaceutical
1363 articles with Takeda Pharmaceutical
-
Two therapies for different cancers are moving forward in development following positive outcomes in their clinical trials ahead of the ASCO's annual meeting in early June 2022.
-
Takeda and Seagen to Highlight ADCETRIS® Combination Data Showing Statistically Significant Improvement in Overall Survival (OS) for Patients with Advanced Hodgkin Lymphoma
5/26/2022
Takeda Pharmaceutical Company Limited (TSE:4502) and Seagen Inc., (NASDAQ:SGEN) today announced that overall survival (OS) data from the Phase 3 ECHELON-1 clinical trial of an ADCETRIS® (brentuximab vedotin) plus chemotherapy combination will be presented in an oral session at the 59th American Society of Clinical Oncology (ASCO) Annual Meeting on Friday, June 3, 2022, 1:00-4:00 PM CT, and at the 27th European Hematology Association (EHA) Annual Meeting.
-
This summer, BioSpace will release a series of reports looking at the current state of diversity and inclusion in the life sciences.
-
Takeda Delivers Strong FY2021 Results; Continued Growth Momentum Expected in FY2022
5/11/2022
Takeda announced strong financial results for fiscal year 2021, driven by the performance of its growth products, new product launches and strength across its key business areas.
-
In its financial results for 2021, Takeda announced that it has decided to discontinue the development of TAK-609, a therapeutic for Hunter Syndrome.
-
BioCryst's success of its Orladeyo launch in its Q1 report was overshadowed by the news that the FDA had placed a partial clinical hold on three of its clinical trials evaluating BCX9930
-
CENTOGENE and Takeda Extend Market Access and Expansion Partnership to Advance Patient Care Globally
4/28/2022
Centogene N.V. announced it has extended its partnership with Takeda to diagnose patients with rare metabolic and rare neurodegenerative diseases.
-
Takeda Recognized as the 2022 ISPE Facility of the Year Awards Winner in Two Categories
4/26/2022
Takeda announced that the International Society for Pharmaceutical Engineering has awarded the company top honors in the Supply Chain and Pharma 4.0™ categories for the 2022 Facility of the Year Awards.
-
Takeda Presents New Exploratory Analysis Showing Patients Treated With LIVTENCITY™ (Maribavir) Had Reductions in Hospitalization Rates and Length of Hospital Stay
4/22/2022
Takeda (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it will present four company-sponsored abstracts at the Tandem Transplantation & Cellular Therapy Meetings in Salt Lake City, Utah, and the 32nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Lisbon, Portugal between April 23 and 26, 2022.
-
Genetic varations within the human genome is littered with breadcrumbs leading right up to new therapeutic possibilities.
-
Takeda Announces Approval of Nuvaxovid® COVID-19 Vaccine for Primary and Booster Immunization in Japan
4/19/2022
Takeda announced that it has received manufacturing and marketing approval from the Japan Ministry of Health, Labour and Welfare for Nuvaxovid® Intramuscular Injection, a novel recombinant protein-based COVID-19 vaccine, for primary and booster immunization in individuals aged 18 and older.
-
Takeda’s TAKHZYRO® (lanadelumab-flyo) Prefilled Syringe Now Available for People With Hereditary Angioedema (HAE) Ages 12 Years and Older in the United States
4/18/2022
Takeda (TSE:4502/NYSE:TAK) today announced TAKHZYRO® (lanadelumab-flyo) injection single-dose prefilled syringe is now available in the U.S. to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older.
-
It was a very busy week for clinical trial news, with much of it coming out of the American Association of Cancer Research Annual Meeting. Read on for details.
-
Ubix Therapeutics has announced a collaboration agreement with SK Biopharmaceuticals, and Engitix and Takeda are teaming up to develop a therapeutic for fibrostenotic IBD.
-
Takeda Announces Completion of Acquisition of Own Shares - Apr 13, 2022
4/13/2022
Takeda Pharmaceutical Company Limited provided an update on the status and announced the completion of the acquisition of its own shares, which has been carried out pursuant to the provision of its Articles of Incorporation in accordance with Article 459, paragraph 1 of the Companies Act of Japan, based on the resolution of the Board of Directors’ meeting held on October 28, 2021. Details of the acquisition of shares is below.
-
Takeda’s TAKHZYRO® (lanadelumab) Open Label Phase 3 Study Met Its Objectives in Children Ages 2 to <12 Years of Age With Hereditary Angioedema (HAE)
4/12/2022
Takeda’s TAKHZYRO ® (lanadelumab) Open Label Phase 3 Study Met Its Objectives in Children Ages 2 to <12 Years of Age With Hereditary Angioedema (HAE).
-
Engitix Announces Expanded Collaboration and Licensing Agreement with Takeda to Develop New Anti-Fibrotic Therapies in Inflammatory Bowel Disease
4/12/2022
Engitix Ltd, a biotechnology company developing a portfolio of programmes in fibrosis and solid tumours using its proprietary human extracellular matrix platform, entered into an agreement with Takeda to expand an existing collaboration to now include the discovery and development of novel therapeutics for fibrostenotic inflammatory bowel disease, including Crohn’s disease and ulcerative colitis.
-
The trial demonstrated a safety profile in the younger age group as seen in patients 12 and older, with no severe side effects and no one dropping out from adverse events.
-
Evozyne inked a partnership with Takeda Pharmaceutical to develop next-generation gene therapies for up to four rare disease targets. Continue reading for that and more collaboration news from this week.
-
Takeda and the New York Academy of Sciences Announce 2022 Innovators in Science Award Winners
4/5/2022
Takeda and the New York Academy of Sciences Announce 2022 Innovators in Science Award Winners.